融捷健康(300247.SZ):擬將募投項目結項並將節餘募集資金永久補充流動資金
格隆匯4月22日丨融捷健康(300247.SZ)公佈,公司於2025年4月21日召開第六屆董事會第十三次會議和第六屆監事會第十次會議,審議通過了《關於募集資金投資項目結項並將節餘募集資金永久補充流動資金的議案》,同意公司將募投項目“收購上海瑞宇健身休閒用品有限公司股權項目”、“收購深圳市福瑞斯保健器材有限公司項目”、“綜合辦公與產品體驗服務中心建設項目”、“產業併購與孵化資金項目”、“補充上市公司流動資金項目”結項,並將節餘募集資金351.22萬元(含累計收到的利息收入扣除銀行手續費等的淨額,實際金額以資金劃轉日銀行結算金額爲準)永久補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.